Document is current
Any future updates will be listed below
-
Authors
Shukla, Shirish
Ying, Weijiang
Gray, Felicia
Yao, Yiwu
Simes, Miranda L. https://orcid.org/0000-0002-0410-0864
Zhao, Qingjie
Miao, Hongzhi
Cho, Hyo Je
González-Alonso, Paula https://orcid.org/0000-0002-5343-8300
Winkler, Alyssa
Lund, George
Purohit, Trupta
Kim, EunGi
Zhang, Xiaotian
Ray, Joshua M.
He, Shihan
Nikolaidis, Caroline
Ndoj, Juliano
Wang, Jingya
Jaremko, Łukasz https://orcid.org/0000-0001-7684-9359
Jaremko, Mariusz
Ryan, Russell J. H. https://orcid.org/0000-0001-8174-3962
Guzman, Monica L. https://orcid.org/0000-0002-9262-8246
Grembecka, Jolanta https://orcid.org/0000-0002-6180-9095
Cierpicki, Tomasz https://orcid.org/0000-0003-2058-0658
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA201204, CA244254, CA160467, CA226759, CA240514)
Leukemia and Lymphoma Society (1340-17)
- License Information
-
More Information
Article History
Received: 21 April 2020
Accepted: 10 May 2021
First Online: 21 June 2021
Competing interests
: W.Y., Y.Y., F.G., Q.Z., J.G. and T.C. are co-inventors on a patent application for PRC1 inhibitors.
